- Ritter Pharmaceuticals - http://www.ritterpharmaceuticals.com -

Press Releases / News

Press Releases / News

2018

May – Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance [1]

May – Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates [2]

May – Ritter Pharmaceuticals Selects Medpace as its Clinical Research Organization for Pivotal Phase 3 Clinical Trial of RP-G28 in Lactose Intolerance [3]

March – Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split [4]

March – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update [5]

March – Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome [6]

March – Ritter Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13 [7]

March – Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split [8]

February – Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, M.D., to Medical Advisory Board [9]

January – Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial [10]

2017

November – Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017 [11]

November – Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress [12]

October – Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update [13]

October – Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance [14]

September – Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering [15]

August – Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance [16]

August – Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update [17]

August – Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms [18]

May – Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates [19]

May – Ritter Pharmaceuticals Announces Issuance of New Patents for its Lactose Intolerance Treatment, RP-G28, and Provides an Update on its Path Forward into Phase 3 [20]

April – Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities [21]

March – Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial [22]

February – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update [23]

February – Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy [24]

January – Ritter Pharmaceuticals to Ring Today’s Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month [25]

January – Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome [26]

January – Ritter Pharmaceuticals Appoints William Merino, Ph.D., to its Board of Directors [27]

January – Ritter Pharmaceuticals Phase 2a Lactose Intolerance Clinical Trial Microbiome Data, Published in Proceedings of the National Academy of Sciences [28]

2016

November – CNBC Article by Andrew Ritter: A Race to Turn Trillions of Our Own Bacteria into Medical Breakthroughs [29]

November – Ritter Pharmaceuticals, Inc. to Present at the 9th Annual LD Micro Main Event on December 7, 2016 [30]

November – Ritter Pharmaceuticals, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update [31]

October – Ritter Pharmaceuticals, Inc. Prices $5,000,000 Public Offering of Common Stock [32]

October – Ritter Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock [33]

October – Ritter Pharmaceuticals Concludes Last Patient Visit of its Phase 2b/3 Clinical Trial of RP-G28 for the Treatment of Lactose Intolerance [34]

October – Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum [35]

August – Ritter Pharmaceuticals Completes Enrollment for Phase 2b/3 Trial of RP-G28 in  Lactose Intolerance [36]

August – Ritter Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update [37]

June – Ritter Pharmaceuticals Issued Method of Use Patent for RP-G28 [38]

March – Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update [39]

March – Ritter Pharmaceuticals Doses First Patient in Phase 2b/3 Trial of RP-G28 in Lactose Intolerance [40]

March – Ritter Pharmaceuticals Initiates Phase 2B/3 Clinical Trial of RP-G28 in Lactose Intolerance [41]

March – Ritter Pharmaceuticals to Present at the 28th Annual ROTH Conference [42]

March – Ritter Pharmaceuticals, Inc. Featured in PharmaVOICE [43]

February – Ritter Pharmaceuticals Issued Two New Patents [44]

 

2015

December – Ritter Pharmaceuticals Enters Into a $10 Million Common
Stock Purchase Agreement with Aspire Capital Fund

November – Ritter Pharmaceuticals Provides Third Quarter 2015 Financial Results and Business Update [45]

October – Ritter Pharmaceuticals Appoints William J. Sandborn, M.D. to Medical Advisory Board [46]

October – Ritter Pharmaceuticals Appoints AnnKatrin Petersen-Jappelli, M.D., M.SC. as Chief Medical Officer [47]

October – Ritter Pharmaceuticals to Present at the 2015 Aegis Growth Conference [48]

September – Ritter Pharmaceuticals to Present at the 3rd Microbiome R&D Business Collaboration Forum [49]

August – Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor [50]

June – Ritter Pharmaceuticals, Inc. Announces Closing of $20,000,000 Initial Public Offering [51]

April – Ritter Pharmaceuticals Names Gastroenterology Industry Veteran Gerald T. Proehl to its Board of Directors [52]

April – Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors [53]

February – Ritter Pharmaceuticals Names Matthew W. Foehr to its Board of Directors [54]

 

2014

September – Ritter Pharmaceuticals Names Michael D. Step Chief Executive Officer [55]

May – Andrew Ritter Named Finalist for 2nd Consecutive Year in LA Business Journal’s Annual Healthcare Leadership Awards [56]

January – Ritter Pharmaceuticals Announces Publication of Lactose Intolerance Phase 2 Trial in Nutrition Journal [57]

 

2013

October – Using Galacto-Oligosaccharides to Improve Lactose Tolerance: Food Technology [58]

June – Ritter Pharmaceuticals’ Study Shows That Altering the Intestinal Microbiome May Offer an Effective Treatment for Lactose Intolerance [59]

April – Andrew Ritter Named Finalist in LA Business Journal’s Annual Healthcare Leadership Awards [60]

April – Patient Survey: More than 80% Forced to Change Lifestyles Due to Lactose Intolerance [61]

March – Ritter Pharmaceuticals Encouraged by Meeting with FDA [62]

February – Ritter Pharmaceuticals Names Larry Good, M.D. Chief Medical Officer [63]

January – Survey: 75% of People with Lactose Intolerance Avoid Dairy Food [64]

January – Lactose Intolerance: Major Unmet Medical Need [65]

 

2012

July – Ritter Pharmaceuticals Appoints Michael Step to the Board of Directors [66]

May – Ritter Pharmaceuticals Presents Its Phase 2 Study of RP-G28 at Digestive Disease Week 2012 [67]

February – Ritter Pharmaceuticals’ Abstract on RP-G28’s Phase 2 Trial Selected for Oral Presentation at Digestive Disease Week 2012 [68]

January – Ritter Pharmaceuticals’ RP-G28 Improves Lactose Intolerance Symptoms and Lactose Digestion in Phase 2 Trial [69]

 

2011

December – Ritter Pharmaceuticals Appoints Robert H. Tidwell as Chief Business Officer [70]

November – Ritter Pharmaceuticals Completes Phase 2 Trial for Lactose Intolerance [71]

June – Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance [72]

 

2010

November – Ritter Pharmaceuticals, Inc. Awarded a Grant under the U.S. Qualified Therapeutic Discovery Project Program [73]

October – Ritter Pharmaceuticals, Inc. Wins Top Awards at Venture Capital Investment Competition [74]

October – Ritter Pharmaceuticals Wins 2010 San Diego Quick Pitch Competition [75]

June – Ritter Pharmaceuticals, Inc. Receives FDA IND Approval For Lactose Intolerance Treatment [76]

February – Ritter Pharmaceuticals, Inc. to Discuss Lactose Intolerance and Associated Health Risks at NIH Conference [77]

 

2009

September – Ritter Pharmaceuticals’ CEO, Andrew Ritter to Present at the 11th Annual SoCalBio Investor Conference [78]

September – Ritter Pharmaceuticals, Inc. Hires Dr. Howard Foyt as Exec VP, Development & Chief Medical Officer [79]